Acquisition Completed
Ensysce Biosciences acquisition of Cy Biopharma
Announced 6 Aug 2026
Advisers
Ensysce Biosciences
Acquirer
- Financial adviser
- Legal adviser
Other advisers
- Fairness opinion
- Target
- Cy Biopharma
- Acquirer
- Ensysce Biosciences
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 6 Aug 2026
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
- M&A financial advisers, 2026 to date Wedbush Securities #95 · Tungsten Advisors #145
- M&A financial advisers, completed, 2026 to date Tungsten Advisors #104 · Wedbush Securities #104
- M&A legal advisers, 2026 to date Troutman Pepper Locke #39 · Orrick #81
- M&A legal advisers, completed, 2026 to date Troutman Pepper Locke #75 · Orrick #140
- Fairness opinion providers, 2026 to date H.C. Wainwright & Co. #25
Similar deals
- Leyden Labs acquisition of RIGImmune Sep 2026 · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novo Nordisk stake in Orbis Medicines Sep 2026 · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech

